CAR-T细胞免疫疗法在肿瘤中的研究进展  

The research progress of CAR-T cellular immunotherapy in oncology

作　　者：王顺娜 史婷婷 伍杨 郑晓凤[3] 张久聪 WANG Shunna;SHI Tingting;WU Yang;ZHENG Xiaofeng;ZHANG Jiucong(Department of Gastroenterology,The 940th Hospital of Joint Logistic Support Force of PLA,Lanzhou 730050,China;The First Clinical College of Medicine,Gansu University of Traditional Chinese Medicine,Lanzhou 730000,China;Department of Gastroenterology,Second Hospital of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]中国人民解放军联勤保障部队第九四〇医院消化内科,兰州730050 [2]甘肃中医药大学第一临床医学院,兰州730000 [3]兰州大学第二医院消化内科,兰州730030

出　　处：《生命的化学》2024年第11期2018-2025,共8页Chemistry of Life

基　　金：甘肃省青年科技基金项目(23JRRA1673);联勤保障部队第九四〇医院拔尖项目(2021yxky002);中央高校优秀青年团队培育项目(31920220065);兰州市青年科技人才创新重点项目(2023-2-29)。

摘　　要：血液系统恶性肿瘤疾病的治疗一直以来是研究的难点,也是研究的热点。近年来,随着嵌合抗原受体-T(chimeric antigen receptor-T,CAR-T)细胞免疫疗法的推进,在白血病、骨髓瘤和非霍奇金B细胞淋巴瘤等血液系统恶性肿瘤中,过继CAR-T细胞免疫疗法在难治性患者化疗方面表现出显著疗效。同时,在实体肿瘤方面,CAR-T细胞免疫疗法也逐渐发展起来,越来越深入临床研究。因此,本文就近年来CAR-T细胞免疫疗法的机制、局限性及在肿瘤中的研究进展进行综述,以供临床医生参考。The treatment of haematological malignant diseases has always been a difficult and hot research topic.In recent years,with the advancement of chimeric antigen receptor(CAR)-T cell immunotherapy,in haematological malignancies such as leukaemia,myeloma and non-Hodgkin’s B-cell lymphoma,over-thecounter CAR-T cell therapies have demonstrated significant efficacy in chemotherapy for refractory patients.Meanwhile,in solid tumours,CAR-T cell immunotherapy has also been gradually developed and increasingly delved into clinical studies.Therefore,this work provides an overview of the mechanisms,limitations and research progress of CAR-T cell immunotherapy in oncology in recent years for clinicians’reference.

关 键 词：嵌合抗原受体-T细胞 免疫疗法 局限性 实体肿瘤 

分 类 号：R730.51[医药卫生—肿瘤]